Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions
文献类型：期刊论文
| 作者 | Huang, Jindi3; Chen, Liye3; Wu, Jiangxia3; Ai, Daiqiao3; Zhang, Ji-Quan1; Chen, Tie-Gen2; Wang, Ling3 |
| 刊名 | JOURNAL OF MEDICINAL CHEMISTRY
 |
| 出版日期 | 2022-12-12 |
| 页码 | 29 |
| ISSN号 | 0022-2623 |
| DOI | 10.1021/acs.jmedchem.2c01070 |
| 通讯作者 | Wang, Ling(lingwang@scut.edu.cn) |
| 英文摘要 | The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway is one of the most important intracellular pathways involved in cell proliferation, growth, differentiation, and survival. Therefore, this route is a prospective biological target for treating various human diseases, such as tumors, neurodegenerative diseases, pulmonary fibrosis, and diabetes. An increasing number of clinical studies emphasize the necessity of developing novel molecules targeting the PI3K/AKT/mTOR pathway. This review focuses on recent advances in ATP-competitive inhibitors, allosteric inhibitors, covalent inhibitors, and proteolysis-targeting chimeras against the PI3K/AKT/mTOR pathway, and highlights possible solutions for overcoming the toxicities and acquired drug resistance of currently available drugs. We also provide recommendations for the future design and development of promising drugs targeting this pathway. |
| WOS关键词 | ADVANCED SOLID TUMORS ; 1ST-IN-HUMAN PHASE-I ; PHOSPHATIDYLINOSITOL 3-KINASE PI3K ; SELECTIVE PI3K-DELTA INHIBITOR ; ORALLY BIOAVAILABLE INHIBITOR ; RAPAMYCIN KINASE INHIBITOR ; ATP-COMPETITIVE INHIBITOR ; MAMMALIAN TARGET ; HIGHLY POTENT ; BIOLOGICAL EVALUATION |
| 资助项目 | National Natural Science Foundation of China ; Natural Science Foundation of Guangdong Province ; [81973241] ; [2020A1515010548] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000895919400001 |
| 出版者 | AMER CHEMICAL SOC |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/304327]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Wang, Ling |
| 作者单位 | 1.Guizhou Med Univ, Coll Pharm, Guiyang 550004, Peoples R China 2.Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Mat Med, Zhongshan 528400, Guangdong, Peoples R China 3.Univ Technol, Guangdong Prov Engn & Technol Res Ctr Biopharmaceu, Guangdong Prov Key Lab Fermentat & Enzyme Engn, Sch Biol & Biol Engn,Joint Int Res Lab Synthet Bio, Guangzhou 510006, Peoples R China |
| 推荐引用方式 GB/T 7714 | Huang, Jindi,Chen, Liye,Wu, Jiangxia,et al. Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions[J]. JOURNAL OF MEDICINAL CHEMISTRY,2022:29. |
| APA | Huang, Jindi.,Chen, Liye.,Wu, Jiangxia.,Ai, Daiqiao.,Zhang, Ji-Quan.,...&Wang, Ling.(2022).Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions.JOURNAL OF MEDICINAL CHEMISTRY,29. |
| MLA | Huang, Jindi,et al."Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions".JOURNAL OF MEDICINAL CHEMISTRY (2022):29. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。